Determining Whether Multiple Anesthesia Exposures Affect Cognitive Function for Retinoblastoma Patients
Launched by MEMORIAL SLOAN KETTERING CANCER CENTER · Jun 1, 2018
Trial Information
Current as of June 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how multiple exposures to anesthesia might affect brain development in children who have been treated for retinoblastoma, a type of eye cancer. The researchers want to compare the brain development of children who have had several anesthesia experiences during their treatment to those who have never had anesthesia. This study is important because it may help us understand if repeated anesthesia affects cognitive function, which is how well the brain works.
To participate in this study, children must be between 6 and 17 years old and have a diagnosis of retinoblastoma. However, children with certain health conditions, previous cancers, or specific surgeries won't be eligible. If a child joins the study, they can expect to undergo tests that assess their cognitive function. It's also worth noting that while the study is open to all children, those whose parents speak only Spanish can still participate, as materials for parents will be available in Spanish. This research could provide valuable insights into the care of children treated for retinoblastoma.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥ 6 and \< 17 years old
- Exclusion Criteria:
- • Diagnosis of any secondary disease associated with developmental delay
- • History of second cancer diagnosis
- • Legal Blindness
- • Past surgery of any type, with the exception of enucleation for retinoblastoma
- • Past exposure to anesthesia for purposes other than retinoblastoma examination
- • More than one anesthesia encounter before diagnosis at MSK
- • Past External Beam Radiation for treatment of retinoblastoma
- • Past systemic chemotherapy
- • Non-native speaker of English; however, children whose parents speak only Spanish will be included, because the tests for parents are available in Spanish
About Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center (MSKCC) is a world-renowned institution dedicated to cancer treatment, research, and education. As a leading clinical trial sponsor, MSKCC focuses on advancing innovative cancer therapies through rigorous scientific investigation and collaboration. The center's multidisciplinary team of experts employs cutting-edge methodologies to design and conduct trials that aim to improve patient outcomes and enhance understanding of cancer biology. With a commitment to translating research findings into clinical practice, MSKCC plays a pivotal role in shaping the future of oncology care and ensuring that patients have access to the latest therapeutic advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New York, New York, United States
Patients applied
Trial Officials
Vittoria Arslan Carlon, MD
Principal Investigator
Memorial Sloan Kettering Cancer Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials